The Medicines Company Культура компании

Dr. Clive A. Meanwell, M.D., Ph.D. has been the Chief Executive Officer of The Medicines Company since August 2004. Dr. Meanwell served as President of the firm since October 2009 and served as its Chief Executive Officer from August 2004 to December 2004 and served as Co-Chief Executive Officer and President from 1996 to September 2001. Dr. Meanwell served as the President of Targanta Therapeutics Corp. since February 25, 2009 He worked at Applied Molecular Evolution, Inc. From 1995 to 1996, he was a Founding Partner and Managing Director at MPM Capital. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche Inc. including Senior Vice President from 1992 to 1995, Vice President from 1991 to 1992 and Director of Product Development from 1986 to 1991. He served as the Chairman of The Medicines Company from September 2001 to August 31, 2015. He has been a Director of Medicines Company since July 1996. He served as a Director of Applied Molecular Evolution, Inc. He served as the Executive Chairman of Medicines Company from September 2001 to August 2004. He has been Vice Chairman of BB Biotech AG since 2011. He has been Director of Endo Pharmaceuticals Solutions Inc. since January 2003 and BB Biotech AG since 2004. He serves as a Director of Hoffmann-La Roche Limited. He served as a Director of Targanta Therapeutics Corp. since February 25, 2009 and Endo Pharmaceuticals Holdings Inc. from 2003 to May 27, 2010. He worked in the Department of Medicine at The Queen Elizabeth Medical Center and associated hospitals. He served as Director of Scientific and Development Advisory Board of Maxim Pharmaceuticals Inc. since February 6, 2003. Dr. Meanwell holds an M.D. and a Ph.D. from the University of Birmingham, United Kingdom, where he also trained in Medical Oncology.

Mr. Christopher T. Cox, also known as Chris, has been the Chief Corporate Development Officer and Executive Vice President of The Medicines Company since February 2016. Mr. Cox serves as a Managing Member of WC Capital, LLC. Mr. Cox served as the Chairman of Corporate Department at Cadwalader, Wickersham & Taft LLP. He was a Partner at Cadwalader, Wickersham & Taft LLP since January 2012. He joined Cadwalader in January 2012. Prior to joining MDCO, Mr. Cox spent over 20 years as a Corporate Attorney. Previously, he served as a Partner at Cahill Gordon & Reindel LLP. Mr. Cox has extensive experience in a wide array of corporate, financial and business-related matters, including mergers and acquisitions, joint ventures, restructurings, spin-offs and IP licensing and monetization transactions. He advised public and private companies, private equity firms and financial institutions in U.S. and cross-border mergers, acquisitions, dispositions, joint ventures, capital raising transactions and strategic investments, as well as a wide range of governance, compliance and other business-related matters. He has been a Director of Datawatch Corporation since August 21, 2012. He has been selected by The American Lawyer as a ???Dealmaker of the Year??? and was named an M&A Atlas Top 50 Global M&A Lawyer. He has been named a leading lawyer by the Lawdragon 500 Annual Guide. He has been recognized for his work in mergers, acquisitions and buyouts by The Legal 500. Mr. Cox holds BS and J.D. from the University of Missouri, where he was a Member of the Missouri Law Review.

Mr. Stephen M. Rodin, J.D. serves as Executive Vice President of The Medicines Company. Mr. Rodin has been General Counsel and Secretary at The Medicines Company since March 3, 2014. Mr. Rodin served as Senior Vice President at The Medicines Company since March 3,2014. Mr. Rodin served as Vice President and Deputy General Counsel of The Medicines Company until March 3, 2014. He was an Associate of Proskauer Rose LLP. Mr. Rodin holds BA in 1997 from Georgetown University and a JD in 2002 from Vanderbilt University School of Law.

Mr. William B. O'Connor, also known as Bill, has been the Chief Financial Officer of the Medicines Company since January 1, 2016. Mr. O'Connor served as a Senior Vice President of the Medicines Company and its Chief Accounting Officer since March 2008 until 2016. Mr. O'Connor joined Medicines Co. in April 2006 as Vice President of Finance and Controller. Mr. O'Connor has 14 years of experience in the public accounting sector. From April 2000 to February 2006, he served as Vice President of Finance for Eyetech Pharmaceuticals, Inc. From 1996 to April 2000, Mr. O'Connor worked for Trophix Pharmaceuticals, Inc., a biotech company that specialized in pain medications. He served as a Director of Medicines Co. Mr. O'Connor is a certified public accountant and received a B.S. in accounting from Fairleigh Dickinson University.

Dr. Fredric N. Eshelman, also known as Fred, Pharm.D., serves as Chairman of Eyenovia, Inc. and also has been its Director since December 2014. Dr. Eshelman has been the Chief Executive Officer of Innocrin Pharmaceuticals Inc. since March 15, 2017. Dr. Eshelman is the Founder and Principal of Eshelman Ventures, LLC. Dr. Eshelman served as the Chief Executive Officer and Executive Chairman of Pharmaceutical Product Development Inc. from July 1, 1990 to July 2009. He served as an Executive Chairman of Furiex Pharmaceutical Inc. Dr. Eshelman founded Pharmaceutical Product Development Inc.'s predecessor and served as the Chief Executive Officer until 1989. He served as the Senior Vice President, Development of Glaxo Inc. and held various roles in drug development with other pharmaceutical companies such as Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. He has been an Executive Chairman of The Medicines Company since November 15, 2017. He served as the Non-Executive Chairman of The Medicines Company since August 31, 2015. He has been the Founding Chairman of Furiex Pharmaceuticals, Inc. since 2009 and has been its Director since October 2009. He served as Vice Chairman of Pharmaceutical Product Development from July 1993 to July 2009 and its Director since July 1990. He has been an Independent Director of Valeant Pharmaceuticals International, Inc. since March 8, 2016. He serves as the Director at Asepticys, Inc. He has been a Director of G1 Therapeutics Inc. since February 5, 2015 and Innocrin Pharmaceuticals Inc. since April 15, 2015. He serves on a number of industry boards, including the Association of Clinical Research Organizations. He is a Member of Advisory Board of Auven Therapeutics Management L.L.L.P and Princeton Biopharma Capital Partners LLC. Most recently, he was appointed Chairman of The Medicine's Company. Dr. Eshelman serves as a Director of Meryx Inc., He serves on the Board of visitors for the School of Pharmacy at the University of North Carolina. In addition, he chairs the board of visitors for the School of Pharmacy at UNC-CH. He served as a Director of Spotlight Health, Inc. and Takeda California, Inc. Dr. Eshelman served as a Director of Glaxo Inc. from 1989 to 1990 and served as a Director of Accelerator Corporation and Takeda San Diego, Inc. Dr. Eshelman served as a Director of PrimeCyte Inc. and Aton Pharma, Inc. He was on the Board of Trustees for UNC-W and in 2011 was appointed by the NC General Assembly to serve on the Board of Governors for the state's multi-campus university system as well as the NC Biotechnology Center. He has received many awards including the Davie and Distinguished Service Awards from UNC, NC Entrepreneur Hall of Fame Award and Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy. He has a Doctorate of Pharmacy from the University of Cincinnati and a BS in Pharmacy from the University of North Carolina at Chapel Hill in 1972 and a Graduate of the Owner President Management program at Harvard Business School.

Mr. Jeffrey A. Frazier, also known as Jeff, has been an Executive Vice President and Chief Human Strategist Officer at The Medicines Company since June 2014. Mr. Frazier serves as Vice President of Human Resources at Novo Nordisk Pharmaceuticals Inc. Mr. Frazier served as Vice President of Human Resources at Novo Nordisk A/S since June 2004 until 2014. He served as Corporate Vice President of Human Resources and Public Affairs at Novo Nordisk A/S. He served as Head of human resources at Pharmacia Corporation's (now Pfizer Inc.), Global Pharmaceutical Business unit, where he has held national and international leadership positions for 14 years. He served as Vice President of Human Resources at Novo Nordisk Inc. from 2004 to 2014. He served at Novo Nordisk as Head of human resources, global pharmaceutical business, international. He served as Executive Director of staffing and diversity. He established and led a new corporate human resources function to ensure the availability of talented people following an acquisition. He served as head of global research and development, human resources. He also served at Novo Nordisk as Director of Corporate Human Resources in Sweden and the United Kingdom and Director of Human Resources in Dublin, Ohio. Mr. Frazier received a Bachelor's Degree in business administration, human resources from Kent State University in Ohio.

Dr. Stephanie Plent M.D. serves as Executive Vice President and Chief Value Officer of The Medicines Company. Dr. Plent has been a Vice President of Medicines Co. since July 2002 with a focus on medical policy and economics. Dr. Plent joined Medicines Co. in July 2000. Dr. Plent spent six years as Medical Director for Disease Management, Aetna US Healthcare Inc., an insurance company and before that as a consultant in the Health Care Practice at Arthur D. Little Inc., a consulting firm. Dr. Plent received her medical degree from the Royal Free Hospital School of Medicine, United Kingdom.

Ms. Nancye Green serves as Executive Vice President of the Medicines Company. Ms. Green leads global communications & information architecture for The Medicines Company (MDCO). She served as Chief Executive Officer of Waterworks Inc. A designer and business leader, she has had a storied career addressing the complex communication challenges of large enterprises, startup companies and non-profit organizations across industries. She served as a Founding Partner and Chief Executive Officer of Donovan/Green. She began her professional career as a designer, founding Donovan and Green, a design and marketing communications firm specializing in branding, brand strategy, environmental design and information architecture. Clients included Pleasant Company, Sony, Procter & Gamble and American Express. Ms. Green served as a Director of Waterworks Operating Company LLC (formerly Pds Associates, Inc.). She serves on the Boards of Directors of Hallmark Cards and Wildlife Trust, the Design Advisory Board of Procter & Gamble and the Advisory Board of Bayer Healthcare Diabetes Care Division. She served on the Board of Directors for D'Arcy Worldwide and is past President of both the American Institute of Graphic Arts and the prestigious International Design Conference. She has also received an honorary doctorate from the Corcoran School of Arts in Washington, DC for her contributions to the field of design. She holds degrees from Tulane University and Parsons School of Design.

Dr. T. Scott Johnson, M.D. serves as the Chief Medical Advisor of New Business Ventures at The Medicines Company. Dr. Johnson served as a Vice President of New Business Ventures at The Medicines Company since July 23, 2007 and also served as its Chief Medical Advisor. Dr. Johnson is a Co-Founder and Partner of JSB-Partners, LP. Dr. Johnson has executed a wide range of transactions for pharmaceutical and biotechnology companies, North American and European venture capital firms and private investors. He had a significant career in academic medicine for 15 years prior to moving into the healthcare advisory and investment business in the early 1990s. In September 1991, he Co-founded MPM Capital LP, a private investment banking group focused principally on the biotechnology industry and served as its Managing Director. Dr. Johnson also founded Gilliam Capital LLC, an investment management company in June 2007 and served as its Partner. His activities at MPM centered on private equity and corporate alliance transactions. In 1999, he co-founded JSB Partners. During his tenure at MPM and JSB, he has executed a wide range of transactions involving pharmaceutical and biotechnology companies as well as US and European venture firms and private investors. From 1979 to 1995, he held academic positions at Harvard Medical School, Beth Israel Hospital and Brigham & Women's Hospital, all in Boston. He is board certified in internal medicine, pulmonary diseases, critical care medicine and sleep disorders. He serves on the Board of Directors of MDPad Corporation and MDPad, Inc. He served as a Director of The Medicines Co. from September 1996 to July 23, 2009. He received both his BS and MD at the University of Alabama. Dr. Johnson earned a BS in Chemistry and Mathematics and an MD, Alpha Omega Alpha, at the University of Alabama. He is board certified in internal medicine, pulmonary diseases, critical care medicine and sleep disorders.

Mr. Chris Visioli serves as Senior Vice President of The Medicines Company. Mr. Visioli joined The Medicines Company in June 2003. He has worked in a variety of leadership roles in Medicines Company including business development, finance, investor relations, strategy, planning and business leadership of the anti-platelet team. He has led many efforts in Medicines Company to acquire products and establish partnerships in addition to leading long-term strategy and financial planning work. Prior to joining MDCO, he was a management consultant for Ernst & Young. Mr. Visioli holds a BS in Electrical Engineering from Cornell University and an MBA from Columbia Business School.